Back

State of the art in Empaglifozin in cardiovascular outcomes.

30 August 2016 (14:00 - 14:18)
Organised by:
Congress Presentation Part of: A perspective on the effects of Empaglifozin in cardiovascular outcomes Drug therapy ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor David Fitchett

St. Michael's Hospital, Toronto (Canada)

4 More presentations in this session

Presentation thumbnail
Effect of empagliflozin on heart failure outcomes in subgroups by age: results from EMPA-REG OUTCOME
Doctor P. Monteiro (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Cardiovascular outcomes according to LDL cholesterol levels in EMPA-REG OUTCOME
Doctor G. Langslet (Oslo, NO)
Abstract Slides Video
Presentation thumbnail
Effect of empagliflozin on cardiovascular death in subgroups by age: results from EMPA-REG OUTCOME
Professor D. Fitchett (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
Future direction for research in Empaglifozinon heart failure treatment.
Associate Professor P. Sarafidis (Thessaloniki, GR)
Slides Video

Access the full session

Session thumbnail
A perspective on the effects of Empaglifozin in cardiovascular outcomes

The Event

Event poster

ESC Congress 2016

30 August 2016 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Empagliflozin in a real-world chronic heart failure population
3 September 2019
thumbnail
Congress Session
Young Investigator Award (YIA) Basic Science
17 May 2025
thumbnail
Congress Session
A multidisciplinary approach to type 2 diabetes, obesity, and cardiovascular diseases: current evidence and a glimpse into the future
27 August 2023
thumbnail
Webinar
Early initiation of SGLT-2 inhibitors after acute decompensated heart failure
26 October 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources